The National Institutes of Health (NIH) has launched a large international study - IMPAACT 2010 or VESTED (Virologic Efficacy and Safety of Antiretroviral Therapy Combinations with TAF/TDF, EFV and DTG) – to evaluate the current preferred first-line regimen (efavirenz (EFV), lamivudine (3TC) or emtricitabine (FTC), and tenofovir disoproxil fumarate (TDF) for pregnant women recommended by the World Health Organization (WHO) and two regimens containing a newer drug, dolutegravir (DTG), and either tenofovir alafenamide (TAF)… (NIH, January 24, 2018)